Target intelligence / Profile preview

26S proteasome non-ATPase regulatory subunit 12 (PSMD12)

Target
PSMD12
Molecular classification
Proteasome subunit, Enzyme (non-catalytic proteasome regulatory component), Other
01

Overview

26S proteasome non-ATPase regulatory subunit 12 (PSMD12) is a non-ATPase component of the 19S regulator (lid subcomplex) of the 26S proteasome, a large multisubunit protease complex essential for ATP-dependent degradation of ubiquitinated proteins in eukaryotic cells. PSMD12 is required for proper assembly and function of the proteasome, facilitating recognition, deubiquitination, and delivery of target proteins into the 20S catalytic core for proteolysis. It plays a vital role in protein homeostasis, cell cycle, apoptosis, and the generation of antigenic peptides for immune surveillance. Disruption of PSMD12 function (e.g., by haploinsufficient mutations) is linked to intellectual disability, autism spectrum disorder, and related neurodevelopmental syndromes. There are currently no drugs that selectively target PSMD12; most proteasome inhibitors act on the core particle rather than regulatory subunits.

Other names
p55Rpn5STISS26S proteasome regulatory subunit RPN526S proteasome regulatory subunit p55proteasome (prosome, macropain) 26S subunit, non-ATPase, 12
02

Mechanism of action

(not directly targeted by current drugs; most proteasome inhibitors act on the catalytic 20S core, not on PSMD12 or other non-ATPase regulatory subunits)

03

Biological functions

Protein degradation (ubiquitin-proteasome pathway)Protein homeostasisCell cycle regulationApoptosisDNA damage repairAntigen processing (immunoproteasome, MHC class I peptide processing)
04

Disease associations

Neurodevelopmental disorders (including intellectual disability and autism spectrum disorder)Other (potential cancer and neurodegenerative involvement via the proteasome complex)
05

Safety considerations

Loss-of-function mutations are strongly associated with severe neurodevelopmental phenotypes, including intellectual disability and autismEssential for proteasome function: general inhibition or loss could induce toxicity due to disrupted protein homeostasis
06

Biomarkers

Potential biomarker for neurodevelopmental disorders when mutatedNo widely recognized clinical biomarkers specific to PSMD12

Beyond the preview

Go deeper on 26S proteasome non-ATPase regulatory subunit 12 (PSMD12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 12 (PSMD12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call